Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Cardio-Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1520687

This article is part of the Research Topic Targets in Cardio-Oncology: Drug Effects and Mechanisms of Action View all 8 articles

High-Flow vs Conventional Oxygen Therapies for Acute Cardiogenic Pulmonary Edema Following Hip Fractures and Surgery in Elderly Patients

Provisionally accepted
Caizhe Ci Caizhe Ci 1*Xiao Tong Xiao Tong 2Weiyan Tai Weiyan Tai 1Xiaoyong Geng Xiaoyong Geng 1Yu Han Yu Han 1Xiaojun Zhang Xiaojun Zhang 1
  • 1 Third Hospital of Hebei Medical University, Shijiazhuang, China
  • 2 The First hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China

The final, formatted version of the article will be published soon.

    Purpose: This prospective, randomized controlled study aimed to compare the effects of high-flow oxygen therapy and conventional oxygen therapy in the treatment of acute cardiogenic pulmonary edema following hip fractures and surgery in elderly patients.Methods: From February 2018 to October 2023, 124 patients diagnosed with acute cardiogenic pulmonary edema following hip fractures and surgery were randomly assigned to the high-flow oxygen therapy group (n=62) or conventional oxygen therapy group (n=65).Partial pressure of oxygen (PO2) and blood oxygen saturation (SPO2) were assessed 60 minutes after the treatments. A P value <0.05 was considered statistically significant.Results: There were significant differences in PO2 (66.2±3.3 mmHg vs 62.1±3.4 mmHg, P<0.05) and SPO2 (97.8±2.1 mmHg vs 94.2±1.7 mmHg, P<0.05) between the groups.In the treatment of elderly patients with ACPE following hip fractures and surgery, high-flow oxygen therapy may be performed to improve ventilation when acute cardiogenic pulmonary edema does not significantly improve within 15 minutes of conventional oxygen therapy.

    Keywords: Hip fracture, Acute cardiogenic pulmonary edema, high-flow oxygen therapy, Conventional oxygen therapy, oxygen saturation. Level of Evidence: Therapeutic study, Level Ia

    Received: 31 Oct 2024; Accepted: 26 Feb 2025.

    Copyright: © 2025 Ci, Tong, Tai, Geng, Han and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Caizhe Ci, Third Hospital of Hebei Medical University, Shijiazhuang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more